Dr. Rosenbaum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Bowdoin Square
Sixth Floor
Boston, MA 02114Phone+1 617-726-3482
Summary
- Chief of Psychiatry, MGH; Stanley Cobb Professor of Psychiatry, Harvard Medical School
Massachusetts General Hospital
2002 – Present
Dr. Rosenbaum directs a department of over 600 clinicians and researchers, and 150 trainees, ranked by U.S. News and World Report as the #1 Department of Psychiatry in the United States in 2016 and for 19 of the last 25 years, with 60 specialty clinical and research programs and over 60 million dollars of annual research spending. At MGH, the nation's largest hospital based research institution, with over 900 million dollars of annual research funding, he served as Chair of the Executive Committee on Research. He specializes in mood and anxiety disorders.
He was the 2007 recipient of the C. Charles Burlingame Award given annually for lifetime achievement in psychiatric research and education by the Institute of Living, the 2011 Massachusetts Association of Mental Health Friend and Leader Awardee, and Psychiatrist of the Year for Research from the Massachusetts Psychiatric Society. He is the 2016 recipient of the Joseph B. Martin Dean's Leadership Award for the Advancement of Women Faculty for Harvard Medical School and Harvard School of Dental Medicine and 2018 Ellis Island Medal of Honor awardee.
He served as President and the Chairman of the Board of the Anxiety and Depression Association of America (ADAA), is Chair of the Scientific Council and President of the Board of the American Foundation for Suicide Prevention and a Fellow emeritus of the American College of Neuropsychopharmacology. He served on the Board of Trustees of the Massachusetts General Hospital and on the Board of Trustees of the Partners Healthcare System and is co-Chair of Development at MGH. He directs the Center for Anxiety and Traumatic Stress Disorders at MGH.
He is a co-founder of Psy Therapeutics, to advance the discovery of novel drugs and diagnostics for psychiatric and related disorders.
Education & Training
- Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1974 - 1977
- Yale School of MedicineClass of 1973
- Yale CollegeB.A., 1969
Certifications & Licensure
- MA State Medical License 1975 - 2027
- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Joseph B. Martin Dean's Leadership Award for Advancement of Women's Careers, Harvard Medical School, 2016
- Distinguished Lecturer American Psychiatric Association, 2015
- Outstanding Psychiatrist in Research Massachusetts Psychiatric Society, 2014
- Join now to see all
Publications & Presentations
PubMed
- Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment.Sharmin Ghaznavi, Jeremy N Ruskin, Stephen J Haggerty, Franklin King 4th, Jerrold F Rosenbaum
The American Journal of Psychiatry. 2025-01-01 - Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine.Jerrold F Rosenbaum
The Journal of Clinical Psychiatry. 2024-08-21 - 1 citationsAnxiety Treatment With BenzodiazepinesJerrold F. Rosenbaum
Focus. 2021-06-17
Journal Articles
- Behavioral inhibition in childhood predicts smaller hippocampal volume in adolescent offspring of parents with panic disorderSchwartz CE, Kunwar PS, Hirshfeld-Becker DR, Henin A, Vangel MG, Rauch SL, Biederman J, Rosenbaum JF, Transl Psychiatry, 1/1/2015
- Pharmacological approaches to the challenge of treatment-resistant depressionIonescu DF, Rosenbaum JF, Alpert JE, Dialogues Clin Neurosci, 1/1/2015
- Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record studyCastro VM, Roberson AM, McCoy TH, Wiste A, Cagan A, Smoller JW, Rosenbaum JF, Ostacher M, Perlis RH, Neuropsychopharmacol, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Maintenance treatment of high relapse-prone patientsRosenbaum JF, Sixth World Congress of Biological Psychiatry, Nice, France, 1/1/1997
- Low energy radio waves for the treatment of anxiety: A double-blind studySachs GS, Pasche B, Lafer B, Barbault A, Baldassano CF, Rosenbaum JF, American Psychiatric Association 149th Annual Meeting, New York, NY, 1/1/1996
- Time to remission of depression with acute fluoxetine treatmentRosenbaum JF, Fava M, Quitkin FM, Fawcett J, Amsterdam J, Reimherr FW, Beasley CM, NCDEU 34th Annual Meeting, Psychopharmacology Bulletin, Marco Island, FL, 1/1/1994
- Join now to see all
Lectures
- But we need the eggs: perspectives on what psychiatry has been, can do, and must becomeToronto, Canada - 1/18/2015
- Challenges with mental health treatment for returning veterans in a specialized private outpatient clinicChicago, IL - 1/29/2014
- Ethical dilemmas in psychiatric practiceNew York, NY - 1/6/2014
- Join now to see all
Other
- Combined MGH and McLean Hospital Special Broadcast: Advances in Psychiatry and the Treatment of DepressionRosenbaum JF, Massachusetts General Hospital – Psychiatry Academy, Primedia Healthcare
Boston, MA - 1/7/2007 - Current Controversies in PharmacotherapyRosenbaum JF, Massachusetts General Hospital – Psychiatry Academy, Primedia Healthcare
Dallas, TX - 1/28/2005 - Handbook of Psychiatric Drug Therapy for PDALabbate LA, Rosenbaum JF, Arana GW, and Hyman SE, Lippincott Williams & Willkins
1/1/2005 - Join now to see all
Press Mentions
- Jerrold Rosenbaum, MD: Functional Unblinding in Pivotal Studies and the Future of Psychedelic MedicineSeptember 3rd, 2024
- Newly Revealed Details About Matthew Perry’s Death Put Psychedelics Back in the SpotlightAugust 19th, 2024
- How Do Psychedelics Combat Anxiety and Depression? MGH Researchers Are Determined to Find OutJuly 25th, 2022
- Join now to see all
Grant Support
- Children At Risk For Anxiety Disorders: A Follow UP StudyNational Institute Of Mental Health2007–2008
- Family Imaging Study Of Children At Risk For AnxietyNational Institute Of Mental Health2006–2008
- Children At Risk For Anxiety Disorders: A Follow UP Stu*National Institute Of Mental Health2005–2006
- Children At Risk For Anxiety Disorders:A Follow UP StudyNational Institute Of Mental Health2004
- A Longitudinal Follow UP Of Children At Risk For AnxietyNational Institute Of Mental Health2000–2003
- Course Of Treatment Resistant DepressionNational Center For Research Resources2000–2002
- Follow-Up Of Children At Risk For Anxiety DisordersNational Institute Of Mental Health1999
- Psychopathology In Children Of Agoraphobic ParentsNational Institute Of Mental Health1993–1997
- Adjuncts To Fluoxetine Treatment Of DepressionNational Institute Of Mental Health1994–1996
- Adjuncts To Fluoxetine Trtmt Of Refractory DepressionNational Institute Of Mental Health1992–1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: